Standardized xeno- and serum-free culture platform enables large-scale expansion of high-quality mesenchymal stem/stromal cells from perinatal and adult tissue sources.

Autor: Hoang VT; Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System, Hanoi, Vietnam. Electronic address: v.vanht8@vinmec.com., Trinh QM; Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System, Hanoi, Vietnam., Phuong DTM; Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System, Hanoi, Vietnam; College of Health Science, VinUniversity, Hanoi, Vietnam., Bui HTH; Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System, Hanoi, Vietnam; College of Health Science, VinUniversity, Hanoi, Vietnam., Hang LM; Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System, Hanoi, Vietnam; College of Health Science, VinUniversity, Hanoi, Vietnam., Ngan NTH; Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System, Hanoi, Vietnam; College of Health Science, VinUniversity, Hanoi, Vietnam., Anh NTT; Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System, Hanoi, Vietnam; College of Health Science, VinUniversity, Hanoi, Vietnam., Nhi PY; Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System, Hanoi, Vietnam., Nhung TTH; Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System, Hanoi, Vietnam; College of Health Science, VinUniversity, Hanoi, Vietnam., Lien HT; College of Health Science, VinUniversity, Hanoi, Vietnam., Nguyen TD; College of Health Science, VinUniversity, Hanoi, Vietnam., Thanh LN; Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System, Hanoi, Vietnam; Vinmec HiTech Center, Vinmec Healthcare System, Hanoi, Vietnam., Hoang DM; Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System, Hanoi, Vietnam.
Jazyk: angličtina
Zdroj: Cytotherapy [Cytotherapy] 2021 Jan; Vol. 23 (1), pp. 88-99. Date of Electronic Publication: 2020 Oct 21.
DOI: 10.1016/j.jcyt.2020.09.004
Abstrakt: Background Aims: Mesenchymal stem/stromal cells (MSCs) are of interest for the treatment of graft-versus-host disease, autoimmune diseases, osteoarthritis and neurological and cardiovascular diseases. Increasing numbers of clinical trials emphasize the need for standardized manufacturing of these cells. However, many challenges related to diverse isolation and expansion protocols and differences in cell tissue sources exist. As a result, the cell products used in numerous trials vary greatly in characteristics and potency.
Methods: The authors have established a standardized culture platform using xeno- and serum-free commercial media for expansion of MSCs derived from umbilical cord (UC), bone marrow and adipose-derived (AD) and examined their functional characteristics.
Results: MSCs from the tested sources stably expanded in vitro and retained their biomarker expression and normal karyotype at early and later passages and after cryopreservation. MSCs were capable of colony formation and successfully differentiated into osteogenic, adipogenic and chondrogenic lineages. Pilot expansion of UC-MSCs and AD-MSCs to clinical scale revealed that the cells met the required quality standard for therapeutic applications.
Conclusions: The authors' data suggest that xeno- and serum-free culture conditions are suitable for large-scale expansion and enable comparative study of MSCs of different origins. This is of importance for therapeutic purposes, especially because of the numerous variations in pre-clinical and clinical protocols for MSC-based products.
(Copyright © 2020 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: